• Mashup Score: 0
    Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation - 6 month(s) ago

    BackgroundMany studies have reported the relevance of donor-derived cfDNA (dd-cfDNA) after lung transplantation (LTx) to diagnose and monitor acute rejection (AR) or chronic rejection or infection (INF). However, the analysis of cfDNA fragment size has not been studied. The aim of this study was to determine the clinical relevance of dd-cfDNA and cfDNA size profiles in events (AR and INF) during the first month after LTx.MethodsThis prospective, single-center study includes 62 LTx recipients at the Marseille Nord Hospital, France. Total cfDNA quantification was performed by fluorimetry and digital PCR, dd-cfDNA by NGS (AlloSeq cfDNA-CareDX®), and the size profile by BIABooster (Adelis®). A bronchoalveolar lavage and transbronchial biopsies at D30 established the following groups: not-injured and injured graft (AR, INF, or AR+INF).ResultsQuantification of total cfDNA was not correlated with the patient’s status at D30. The percentage of dd-cfDNA was significantly higher for injured graf

    Source: www.frontiersin.org
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ISHLT
      ISHLT

      2⃣ Federica Pezzuto presents a study from @FrontImmunol by Pascal Pedini et al on the clinical relevance of #ddcfDNA and #cfDNA in evaluating patients after #LungTx. 🫁▶️ https://t.co/cacZ2mNwWp #ISHLT #ISHLTJournalWatch #ISHLTEarlyCareer https://t.co/8tHGSOorNC

  • Mashup Score: 0
    Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas - Clinical Epigenetics - 7 month(s) ago

    Background Early detection has proven to be the most effective strategy to reduce the incidence and mortality of colorectal cancer (CRC). Nevertheless, most current screening programs suffer from low participation rates. A blood test may improve both the adherence to screening and the selection to colonoscopy. In this study, we conducted a serum-based discovery and validation of cfDNA methylation biomarkers for CRC screening in a multicenter cohort of 433 serum samples including healthy controls, benign pathologies, advanced adenomas (AA), and CRC. Results First, we performed an epigenome-wide methylation analysis with the MethylationEPIC array using a sample pooling approach, followed by a robust prioritization of candidate biomarkers for the detection of advanced neoplasia (AN: AA and CRC). Then, candidate biomarkers were validated by pyrosequencing in independent individual cfDNA samples. We report GALNT9, UPF3A, WARS, and LDB2 as new noninvasive biomarkers for the early detection o

    Source: clinicalepigeneticsjournal.biomedcentral.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ManelEsteller
      ManelEsteller

      Glad to have participated in #colorectal #cancer #CRC screening study using DNA #methylation biomarkers in cell-free DNA #cfDNA of more than 400 samples; article published in Clinical Epigenetics @BioMedCentral led by Loretta De Chiara @cinbio_uvigo @uvigo https://t.co/CqBTwWmd6w https://t.co/NY9gyydutH

  • Mashup Score: 6
    Detecting Liver Cancer Using Cell-Free DNA Fragmentomes - 8 month(s) ago

    A machine learning model using multifeature fragmentome data from genome-wide cell-free DNA analyses detected hepatocellular carcinoma with high sensitivity and specificity in average and high-risk populations, including in early-stage disease.

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CD_AACR
      CD_AACR

      Read the article— Detecting #LiverCancer Using Cell-free DNA Fragmentomes, by @ZHFodaMDPhD, @av_annapragada, Amy Kim, @velculescu et al. https://t.co/QFPztlY1gi @hopkinskimmel @HopkinsMedicine #LiquidBiopsy #cfDNA https://t.co/WmQw78SqTP https://t.co/bX8CKIunk4

  • Mashup Score: 8
    Validate User - 8 month(s) ago

    We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CD_AACR
      CD_AACR

      Online First: The origin of highly elevated #cfDNA in healthy individuals and patients with pancreatic, colorectal, lung, or #ovariancancer, by @austinkmattox, Bert Vogelstein et al. https://t.co/yuVwy6SOOs @hopkinskimmel @Ludwig_Cancer #liquidbiopsy https://t.co/LJM1TsnzYM

  • Mashup Score: 0
    The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer - 8 month(s) ago

    Abstract. cfDNA concentrations from patients with cancer are often elevated compared to that of healthy controls, but the sources of this extra cfDNA have never been determined. To address this issue, we assessed cfDNA methylation patterns in 178 patients with cancers of the colon, pancreas, lung, or ovary and 64 patients without cancer. Eighty-three of these individuals had cfDNA concentrations much greater than those generally observed in healthy subjects. The major contributor of cfDNA in all samples was leukocytes, accounting for ~76% of cfDNA, with neutrophils predominating. This was true regardless of whether the samples were derived from patients with cancer or the total plasma cfDNA concentration. High levels of cfDNA observed in patients with cancer did not come from either neoplastic cells or from surrounding normal epithelial cells from the tumor’s tissue of origin. These data suggest that cancers may have a systemic effect on cell turnover or DNA clearance.

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CD_AACR
      CD_AACR

      RT @ElizSMcKenna: ICYMI last week in @CD_AACR - three important papers on #cfDNA/#liquidbiopsy (https://t.co/xqiitVDUJ3), #syntheticlethali…

  • Mashup Score: 12
    A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA - Nature Communications - 1 year(s) ago

    Nucleosome profiling from cell-free DNA (cfDNA) represents a potential approach for cancer detection and classification. Here, the authors develop Griffin, a computational framework for tumour subtype classification based on cfDNA nucleosome profiling that can work with ultra-low pass sequencing data.

    Source: Nature
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NatureComms
      NatureComms

      Recently published: @gavinha et al. develop Griffin, a #computational framework for #tumor subtype classification based on #cfDNA #nucleosome profiling that can work with ultra-low pass #sequencing data #CancerResearch @natrescancer https://t.co/i8774BLCnQ https://t.co/gvJ3FQKVcb

  • Mashup Score: 0
    Detecting Liver Cancer Using Cell-Free DNA Fragmentomes - 1 year(s) ago

    A machine learning model using multifeature fragmentome data from genome-wide cell-free DNA analyses detected hepatocellular carcinoma with high sensitivity and specificity in average and high-risk populations, including in early-stage disease.

    Source: American Association for Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CD_AACR
      CD_AACR

      In the March issue of Cancer Discovery— Detecting #LiverCancer Using Cell-free DNA Fragmentomes, by @ZHFodaMDPhD, @av_annapragada, Amy Kim, @velculescu et al. https://t.co/T7CBQtG2rY @hopkinskimmel @HopkinsMedicine #LiquidBiopsy #cfDNA https://t.co/oKUjVsrXEf

Load More